Clinical trials: Advanced Solid Malignant Tumor
Advanced Solid Tumor
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05231746
- Testing
- hSTC810
- Where
- 5 sites in United States, South Korea
- Volunteers
- 47 people
- Sponsor
- STCube, Inc.
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Solid Tumor
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT06117566
- Testing
- WX390, Toripalimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Cancer, Malignant Tumors
A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 after bolus IV administration, on Day 1 of a 21-day cycle, to patients with advanced solid tumors that have progressed following effective…
- Trial name
- NCT00165802
- Testing
- E7974
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eisai Inc.
Renal Cell Carcinoma (RCC), Lung Cancer
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer
- Trial name
- NCT07181720
- Testing
- CD70-targeted CAR-T cells
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Solid Tumor
KN035 for dMMR/MSI-H Advanced Solid Tumors
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with…
- Trial name
- NCT03667170
- Testing
- KN035
- Where
- 27 sites in China
- Volunteers
- 188 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Solid Tumor, Lymphoma, Non-Hodgkin
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
This study is designed to evaluate the safety and tolerability of QLF31907 injection, to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the recommended phase Ib dose(RPIbD) and…
- Trial name
- NCT05150405
- Testing
- QLF31907
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Cancer, Tumor, Solid
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT06090266
- Testing
- OR502, Cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- OncoResponse, Inc.
Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects…
- Trial name
- NCT07123415
- Testing
- APX-343A, Pembrolizumab
- Where
- 3 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Aptabio Therapeutics, Inc.
Solid Tumor
Autologous Tumour Vaccine Trial
Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid…
- Trial name
- NCT05807035
- Testing
- Radvax
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Vaxine Pty Ltd
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Gastrointestinal Tumors, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06755242
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Bladder Cancer, Urothelial Carcinoma
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
- Trial name
- NCT03980041
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 29 sites in United States, Czechia and 5 more
- Volunteers
- 49 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
B-cell Malignancies, Solid Tumors
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
This Phase I, open-label, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of SYS6005 in advanced malignancies, comprising dose-escalation and expansion phases.
- Trial name
- NCT06958679
- Testing
- SYS6005
- Where
- China
- Volunteers
- 132 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
The primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose…
- Conditions
- Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
- Trial name
- ASCENT-J02 (NCT05101096)
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 36 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors (Including GCTTS)
An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors
This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage.
- Trial name
- NCT05212896
- Testing
- BC006
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
First-in-Human Study of ICT01 in Patients With Advanced Cancer
Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus…
- Trial name
- EVICTION (NCT04243499)
- Testing
- IV ICT01
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 293 people
- Sponsor
- ImCheck Therapeutics, an Ipsen company
Metastatic Solid Tumor
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic…
- Trial name
- NCT04898543
- Testing
- M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.